NCT01836068View on ClinicalTrials.gov

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 22, 2020

Study Completion Date

June 5, 2021

Conditions
HIV
Interventions
DRUG

Enfuvirtide

Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions

Trial Locations (1)

21287

The Sidney Kimmel Comprehensive Cancer Center, Baltimore

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01836068 - Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals | Biotech Hunter | Biotech Hunter